Eric Tam, MD

Keck Medicine of USC, Leukemia and Blood and marrow transplant.

[Eric Tam, MD @EricLTam]

@senalexpadilla NIH funding powers breakthroughs in hematology. Proposed cuts put this progress at risk. Congress must provide strong funding for research in FY 2027 and beyond.

[Eric Tam, MD @EricLTam]

@senadamschiff NIH funding powers breakthroughs in hematology. Proposed cuts put this progress at risk. Congress must provide strong funding for research in FY 2027 and beyond.

[Eric Tam, MD @EricLTam]

@repjudychu NIH funding powers breakthroughs in hematology. Proposed cuts put this progress at risk. Congress must provide strong funding for research in FY 2027 and beyond.

[CancerNetwork® @CancerNetwrk]

A detailed discussion on first-line treatment options for chronic GVHD and options for patients with steroid-refractory chronic GVHD. #GVHD | @EricLTam

https://t.co/uaWkmWJlXP

[Stanford BMT & Cell Therapy @StanfordBMT_CT]

Great work, and kudos to our entire BMT-CT team. https://t.co/j1LBgYuCu5

[Lori Muffly @LoriMuffly]

Early results of an ongoing trial- very exciting, novel approach for MDS/AML!@StanfordCancer

[Surbhi Sidana, MD @SurbhiSidanaMD]

1/ #ASCO21 abstract 8023: We present prelim results from a phase 2 IIT of a novel combination of MGTA-145 and plerixafor for rapid, same day administration -> stem cell mobilization in MM. No need for multiple days of GCSF before mobilization. #mmsm @StanfordBMT_CT

[MDS Hub @MDS_Hub]

CONGRESS|#ASCO21|@LoriMuffly, presented results of phase1 study of JSP191, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allo-HCT. It was safe, well-tolerated, and capable of clearing MDS/AML MRD. #MDSsm, #leusm, @StanfordBMT_CT

[Surbhi Sidana, MD @SurbhiSidanaMD]

Excited to be leading a first in patient trial of this novel mobilization method in heme malignancies— same day mobilization and collection. @StanfordBMT_CT

We will present initial data from this trial in myeloma patients at the upcoming #ASCO21 and EHA meeting

[Blood Journals Portfolio @BloodPortfolio]

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial https://t.co/ylMmgwZ8ib

[Eric Tam, MD @EricLTam]

@LoriMuffly 😱

[Eric Tam, MD @EricLTam]

@BldCancerDoc Now we wait until Jan 20 for engraftment??

[St. George's University @StGeorgesU]

Treating and giving hope to the untreatable—they’re the reasons that Eric Tam, MD ’13, went into medicine in the first place, and what drive him to search for more positive results each day. Read more: https://t.co/JtHDRtdi40

[Blood Advances @BloodAdvances]

Delivering HDAC over 3 or 5 days as consolidation in #AML impacts health care resource consumption but not outcome https://t.co/1GSSZg4PPM

[Bachar Samra, MD @BacharSamra]

Refining ELN in younger #AML
-BCOR- or SETBP1- favorable-risk pts non-CBF, and IDH-mut adverse-risk pts: Intermediate risk
-NPM1/WT1 comut and ZRSR2-mut: adverse
-FLT3-ITD–high allelic ratio: adverse (regardless of NPM1)
-DNMT3A: very poor survival

https://t.co/BNteM0EY4v

[C. Ola Landgren, M.D. @DrOlaLandgren]

FIrst ADC drug for myeloma patients. First BCMA-targeted drug for myeloma patients. FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma. #mmsm https://t.co/zMI6PTYA2b

[ASH @ASH_hematology]

It’s official: #ASH20 will be held as a virtual meeting! While we will miss seeing all of you in person in San Diego, we are excited to reimagine our meeting on an innovative digital platform. Registration reopens 8/31; abstracts now due 8/10 https://t.co/35kF8OQYRc

[Eric Tam, MD @EricLTam]

https://t.co/F61szcqpGk

[Eric Tam, MD @EricLTam]

@BacharSamra I have a transplant joke but it might be rejected

[Eric Tam, MD @EricLTam]

https://t.co/YF0cYN0dXd